Andrea Apolo, M.D. (@apolo

Andrea Apolo, M.D.

12K posts

Andrea Apolo, M.D.

@apolo_andrea

Medical Oncologist, Senior Investigator, Chief, #BladderCancer Section, #GenitourinaryTumors #RareTumors #PatientAdvocate Views are my own

Bethesda, Maryland

Joined March 2014

Pinned
Andrea Apolo, M.D.
@apolo_andrea
May 5
Open #ClinicalTrials for #RareGUtumors #BladderCancer #SmallCell #Squamous #UrachalCa #PenileCancer ⭐️Lurbi +/- Avelumab clinicaltrials.gov/study/NCT06228… ⭐️SG +/- Atezo clinicaltrials.gov/study/NCT06161… ⭐️CaboNivoIpi clinicaltrials.gov/study/NCT02496… ⭐️EV +/- Pembro clinicaltrials.gov/study/NCT06041… ☎️ 301-550-6382
2.3K
Andrea Apolo, M.D.
@apolo_andrea
May 16, 2022
Nivo/Ipi is not superior (by OS) to chemo in PDL1+ cis-ineligible metastatic #bladdercancer pts. Additional endpoints are still maturing. Below is a summary slide of large 1L #CPI randomized trials & outcomes so far. news.bms.com/news/corporate…
Andrea Apolo, M.D.
@apolo_andrea
Sep 19, 2020
Presidential symposium #ESMO20 Phase 3 CheckMate9ER study n= 651 shows first-line CaboNivo vs sunitinib improves PFS (16.6 vs 8.3m), OS (40% decrease risk of death) & ORR (55.7 vs 27.1%). Benefit in all IMDC risks. CaboNivo has potential as 1L tx for #RCC pts @myESMO @DrChoueiri
Andrea Apolo, M.D.
@apolo_andrea
Jun 3, 2022
Beautiful sunset in Chicago @ASCO #ASCO22 @OncoAlert. Can’t wait to see many friends and colleagues. Come to our session tomorrow at 1pm on #Adjuvant therapy for #KidneyCancer and #BladderCancer
Andrea Apolo, M.D.
@apolo_andrea
Jan 26, 2021
Very helpful recently released ⁦@NCCN⁩ #COVID19 vaccination guidelines for patients with #cancer
Andrea Apolo, M.D.
@apolo_andrea
Sep 11, 2020
Just published our Phase I Study of #Cabozantinib & #Nivolumab Alone or With #Ipilimumab for Metastatic #UrothelialCarcinoma & Other GU Tumors. Combination is active & safe & has led to multiple larger ongoing trials in RCC, rare GU tumors, among others ascopubs.org/doi/full/10.12…
Andrea Apolo, M.D.
@apolo_andrea
Sep 19, 2020
As researcher, it is a dream come true for your phase 1 study to go to phase 3 and be positive! Thank you @DrChoueiri for the shoutout! @myESMO #esmo20 @tompowles1 @motzermd @NCIResearchCtr @TiansterZhang @neerajaiims @NCIBillDahut @gulleyj1 @shilpaonc @morr316 @montypal
Toni Choueiri, MD
@DrChoueiri
Sep 19, 2020
Replying to @apolo_andrea @myESMO and 8 others
Dr Apolo is quite modest. Let it be known that her phase 1 trial combining both drugs was instrumental for 9ER and the ongoing #COSMIC313 @apolo_andrea link here ascopubs.org/doi/abs/10.120…
Andrea Apolo, M.D.
@apolo_andrea
Oct 8, 2022
Nivolumab + ipilimumab + cabozantinib triplet combo for untreated advanced #RenalCellCarcinoma pts: Results from a discontinued arm of the phase 3 CheckMate 9ER trial ⁦@DrChoueiri⁩ ⁦@tompowles1⁩ ⁦@BurottoMauricio⁩ ⁦@motzermd⁩ #RCC sciencedirect.com/science/articl…
Andrea Apolo, M.D.
@apolo_andrea
Aug 4, 2020
Thanks @TheLancetOncol! Final version of our article #Cabozantinib in patients with platinum-refractory metastatic #urothelialCarcinoma: an open-label, single-centre, phase 2 trial is now available online for free No sign up or registration required. authors.elsevier.com/a/1bW9a5EIIgBW…
Andrea Apolo, M.D.
@apolo_andrea
Jun 5, 2023
We have a new + Phase 3 #BladderCancer study: #THOR presented by @y_loriot with #erdafinitinib (n=136) vs 2L chemo (n=130) which showed an OS improvement 12.1 mo vs 7.8 mo HR 0.64 mF/U 15.9mo with OS benefit across all subtypes @ASCO #ASCO23 @OncoAlert
23K
Andrea Apolo, M.D.
@apolo_andrea
Feb 13, 2025
Love ❤️ the beautiful tribute to Dr. Felix Feng. We can’t say enough wonderful things about his contributions to #GU #Oncology to science & research! @ASCO #GU25 @OncoAlert @oncodaily @GUOncologyNow @urofocus @oncodaily #FelixFengEndowed @ConquerCancerFd YIA
5.6K
Andrea Apolo, M.D.
@apolo_andrea
Apr 12, 2019
Big day today for #BladderCancer patients. FDA approves first targeted therapy #erdafitinib which showed an ORR of 32% in metastatic post-platinum #BladderCancer patients who have an FGFR3 alterations @FDAOncology fda.gov/Drugs/Informat…
Andrea Apolo, M.D.
@apolo_andrea
Jan 30, 2024
Brief summary of the AMBASSADOR study bpno.dk/medtalks/resul… @OncoAlert @OncBrothers @bergsa83 @morr316 @PGrivasMDPhD @BradMcG04 @ALLIANCE_org @NCIResearchCtr @sonpavde @WilliamKimMD @BladderCancerUS @BladderCancerUK @BladderCancerCA @MTeoMD @bilenma @RandySweisMD @MattGalsky
9.6K
Andrea Apolo, M.D.
@apolo_andrea
Dec 20, 2024
We have several accruing #ClinicalTrials for patients with #SmallCell #BladderCancer 1. #Lurbi +/- #Avelumab LASER clinicaltrials.gov/study/NCT06228… 2. #SG +/- #Atezo SMART clinicaltrials.gov/study/NCT06161… 3. #CaboNivoIpi ICONIC clinicaltrials.gov/study/NCT03866… [email protected] / ☎️240-760-6006
28K